OT-101 (trabedersen) is an antisense oligodeoxynucleotide therapeutic targeting TGF-beta2 mRNA in oncology. It has shown activity in early-phase studies and is being evaluated in ongoing Phase 3 programs across indications such as pancreatic cancer and glioma-related settings. The program remains investigational.
Biotech M&A is shifting toward late-stage CNS and oncology assets with human clinical validation. Oncotelic Therapeutics said it advanced global IP protection for OT-101 and CNS drug delivery.
Oncotelic Therapeutics announced expanded international intellectual property coverage for OT-101 across neurology, oncology and CNS drug-delivery technologies. The company also highlighted biotech valuation trends tied to clinical progress and its 45% stake in GMP Bio.
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation over early-stage programs. Oncology and CNS programs have emerged as strategic M&A targets due to large commercial markets and significant unmet medical needs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06079346 |
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer |
RECRUITING | PHASE2/PHASE3 |
| NCT05425576 |
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition |
NOT_YET_RECRUITING | PHASE2 |
| NCT04801017 |
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects |
UNKNOWN | PHASE2 |
